CD19+ cells are typically co-depleted to diminish the risk of post-transplant lymphoproliferative disease (PTLD), since CD19+ cells can serve as a reservoir for latent Epstein-Barr virus. This evidence concerns the gene CD19 and post-transplant lymphoproliferative disease.